Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DCT002
MIFTS: 58

Ductal Carcinoma in Situ

Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Ductal Carcinoma in Situ

About this section

MalaCards integrated aliases for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ 12 29 15
Noninfiltrating Intraductal Carcinoma 70

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0060074
UMLS 70 C0007124
Sources

Summaries for Ductal Carcinoma in Situ

About this section
Disease Ontology : 12 A breast carcinoma in situ that is characterized by being non-invasive, not having spread outside of the duct into the surrounding breast tissue, has material basis in abnormally proliferating cells, derives from epithelial cells.

MalaCards based summary : Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to comedo carcinoma and in situ carcinoma. An important gene associated with Ductal Carcinoma in Situ is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tamoxifen and Medroxyprogesterone acetate have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and skin, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

Sources

Related Diseases for Ductal Carcinoma in Situ

About this section

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 559)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 33.0 TP53 PGR ESR1 ERBB2
2 in situ carcinoma 31.7 TP53 S100A7 PGR MUC1 KRT5 KRT14
3 squamous cell papilloma 31.7 TP53 KRT14 CDKN2A
4 gynecomastia 31.5 PGR ESR1 ERBB2 CYP19A1
5 breast fibroadenoma 31.5 TP53 PGR KRT14 ESR1 ERBB2 CYP19A1
6 lobular neoplasia 31.4 TP53 PGR MUC1 KRT5 ESR1 ERBB2
7 mammary paget's disease 31.4 PGR MUC1 KRT14 ESR1 ERBB2 EGFR
8 breast ductal carcinoma 31.3 TP53 S100A7 PGR MUC1 KRT5 KRT14
9 papillary carcinoma 31.3 PGR MUC1 ESR1 ERBB2 CDH1
10 intraductal papilloma 31.2 PGR KRT5 KRT14 ESR1 ERBB2 CD44
11 tubular adenocarcinoma 31.2 PGR MUC1 ESR1 ERBB2 EGFR CDH1
12 breast disease 31.1 TP53 PGR KRT5 ESR1 ERBB2 EGF
13 mammographic density 31.0 ESR1 CYP19A1
14 papilloma 31.0 TP53 PTGS2 KRT5 KRT14 ERBB2 EGFR
15 female breast cancer 31.0 TP53 PGR ESR1 ERBB2 CYP19A1 BRCA2
16 hereditary breast ovarian cancer syndrome 30.9 TP53 ERBB2 CDKN2A BRCA2 BRCA1
17 microglandular adenosis 30.8 TP53 PGR ESR1 ERBB2 EGFR CDH1
18 breast adenoid cystic carcinoma 30.8 PGR ESR1 ERBB2
19 bilateral breast cancer 30.8 TP53 PGR ESR1 ERBB2 CDKN2A CDH1
20 vaginal discharge 30.8 PGR ESR1 CYP19A1
21 estrogen excess 30.8 PGR ESR1 CYP19A1
22 adenoma 30.8 TP53 PTGS2 MUC1 CDKN2A CDH1 CCND1
23 hypertrophy of breast 30.7 TP53 PGR ESR1 ERBB2 CYP19A1 BRCA2
24 papillary serous adenocarcinoma 30.7 TP53 PGR BRCA2 BRCA1
25 vulva squamous cell carcinoma 30.7 TP53 EGFR CDKN2A
26 breast adenomyoepithelioma 30.7 KRT5 KRT14
27 exanthem 30.7 ERBB2 EGFR AKT1
28 pleomorphic carcinoma 30.7 TP53 PGR KRT14 EGFR
29 small cell cancer of the lung 30.6 TP53 EGFR CDKN2A AKT1
30 b-lymphoblastic leukemia/lymphoma 30.6 CDKN2A CDH1 BRCA2 BRCA1
31 sarcoma 30.6 TP53 PTGS2 MUC1 CCND1 AKT1
32 cribriform carcinoma 30.6 PGR KRT5 ESR1 ERBB2
33 serous cystadenocarcinoma 30.6 TP53 PGR ERBB2 BRCA2 BRCA1 AKT1
34 pleomorphic adenoma 30.6 TP53 MUC1 KRT14 ERBB2 CDKN2A
35 hidradenoma 30.5 MUC1 KRT5 AKT1
36 insulin-like growth factor i 30.5 ESR1 EGF AKT1
37 breast carcinoma in situ 30.5 TP53 S100A7 PGR KRT5 KRT14 ESR1
38 wilms tumor 1 30.5 TP53 PGR MUC1 ESR1 ERBB2 CDH1
39 adenosquamous carcinoma 30.4 TP53 MUC1 KRT5 EGFR CDKN2A
40 apocrine adenocarcinoma 30.4 PGR MUC1 KRT5 ESR1 ERBB2 EGFR
41 cataract 30.3 TP53 PTGS2 ESR1 EGFR EGF AKT1
42 skin disease 30.2 TP53 S100A7 KRT5 KRT14 EGFR AKT1
43 sporadic breast cancer 30.2 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
44 breast cancer 30.2 TP53 S100A7 PTGS2 PGR MUC1 KRT5
45 adenocarcinoma 30.0 TP53 PTGS2 MUC1 ERBB2 EGFR EGF
46 endometrial cancer 30.0 TP53 PGR MUC1 ESR1 ERBB2 EGFR
47 melanoma 30.0 TP53 ERBB2 EGFR EGF CDKN2A CDH1
48 squamous cell carcinoma 29.9 TP53 S100A7 PTGS2 MUC1 ERBB2 EGFR
49 leukemia, acute myeloid 29.8 TP53 ESR1 ERBB2 EGFR EGF CDKN2A
50 adenoid cystic carcinoma 29.8 TP53 PGR MUC1 KRT5 KRT14 ERBB2

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to Ductal Carcinoma in Situ
Sources

Symptoms & Phenotypes for Ductal Carcinoma in Situ

About this section

GenomeRNAi Phenotypes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.91 EGFR
2 Decreased viability GR00055-A-2 9.91 EGFR
3 Decreased viability GR00221-A-1 9.91 AKT1 CDH1 CDKN2A EGFR ESR1
4 Decreased viability GR00221-A-2 9.91 AKT1 ESR1
5 Decreased viability GR00221-A-3 9.91 AKT1 CDKN2A ERBB2
6 Decreased viability GR00221-A-4 9.91 AKT1 CDKN2A EGFR ESR1 ERBB2
7 Decreased viability GR00249-S 9.91 AKT1
8 Decreased viability GR00301-A 9.91 CDH1
9 Decreased viability GR00386-A-1 9.91 ESR1
10 Decreased viability GR00402-S-2 9.91 CDH1 ESR1

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.51 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
2 endocrine/exocrine gland MP:0005379 10.49 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
3 integument MP:0010771 10.49 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
4 cellular MP:0005384 10.48 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
5 digestive/alimentary MP:0005381 10.47 BRCA1 BRCA2 CCND1 CD44 CDH1 CDKN2A
6 homeostasis/metabolism MP:0005376 10.46 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
7 immune system MP:0005387 10.45 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
8 behavior/neurological MP:0005386 10.43 AKT1 BRCA1 BRCA2 CCND1 CD44 CDKN2A
9 cardiovascular system MP:0005385 10.42 AKT1 BRCA1 CCND1 CD44 CDH1 CDKN2A
10 hematopoietic system MP:0005397 10.41 AKT1 BRCA1 BRCA2 CCND1 CD44 CDKN2A
11 mortality/aging MP:0010768 10.4 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
12 embryo MP:0005380 10.33 AKT1 BRCA1 BRCA2 CDH1 CDKN2A EGFR
13 neoplasm MP:0002006 10.3 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
14 adipose tissue MP:0005375 10.22 AKT1 BRCA1 CYP19A1 EGFR ESR1 KRT14
15 muscle MP:0005369 10.22 AKT1 BRCA1 CD44 CDKN2A CYP19A1 EGFR
16 nervous system MP:0003631 10.21 AKT1 BRCA1 BRCA2 CCND1 CD44 CDKN2A
17 normal MP:0002873 10.21 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
18 limbs/digits/tail MP:0005371 10.18 BRCA1 BRCA2 CD44 EGFR ERBB2 ESR1
19 liver/biliary system MP:0005370 10.11 AKT1 CD44 CDKN2A CYP19A1 EGFR ESR1
20 reproductive system MP:0005389 10.06 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
21 no phenotypic analysis MP:0003012 9.95 CDH1 CDKN2A EGFR ESR1 PGR PTGS2
22 pigmentation MP:0001186 9.87 BRCA1 CD44 CDKN2A CYP19A1 EGFR KRT14
23 renal/urinary system MP:0005367 9.86 BRCA1 CD44 CLDN7 CYP19A1 EGFR ESR1
24 respiratory system MP:0005388 9.7 AKT1 BRCA1 CCND1 CD44 CDKN2A EGFR
25 skeleton MP:0005390 9.44 AKT1 BRCA1 BRCA2 CCND1 CD44 CDKN2A
Sources

Drugs & Therapeutics for Ductal Carcinoma in Situ

About this section

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamoxifen Approved Phase 3 10540-29-1 2733526
2
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
3
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
4
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
5
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
6
Sodium citrate Approved, Investigational Phase 3 68-04-2
7
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
8
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
9 Antineoplastic Agents, Hormonal Phase 3
10 Contraceptive Agents Phase 3
11
Medroxyprogesterone Phase 3 520-85-4 10631
12 Contraceptives, Oral Phase 3
13 Contraceptive Agents, Male Phase 3
14 Antineoplastic Agents, Immunological Phase 3
15 Aromatase Inhibitors Phase 3
16 Immunologic Factors Phase 3
17 Citrate Phase 3
18 Immunoglobulins, Intravenous Phase 3
19 Antibodies Phase 3
20 Immunoglobulins Phase 3
21 Antibodies, Monoclonal Phase 3
22
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
23
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
24
Zoledronic Acid Approved Phase 2 118072-93-8 68740
25
Bazedoxifene Approved, Investigational Phase 2 198481-32-2
26
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
27
Oxytocin Approved, Vet_approved Phase 2 50-56-6 53477758 439302
28
Pasireotide Approved Phase 1, Phase 2 396091-73-9 9941444
29
Somatostatin Approved, Investigational Phase 1, Phase 2 38916-34-6, 51110-01-1 53481605
30
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
31
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
32
Sulforaphane Investigational Phase 2 142825-10-3, 4478-93-7 5350
33
Afimoxifene Investigational Phase 2 68392-35-8
34
Molgramostim Investigational Phase 2 99283-10-0
35 Sulforafan Phase 2
36 Hydroxytamoxifen Phase 2
37 Hormone Antagonists Phase 2
38 Hormones Phase 2
39 Estrogens Phase 2
40 Estrogens, Conjugated (USP) Phase 2
41 Vaccines Phase 2
42 Estrogen Antagonists Phase 2
43 Estrogen Receptor Modulators Phase 2
44 Estrogen Receptor Antagonists Phase 2
45 Tea Phase 2
46 Protein Kinase Inhibitors Phase 2
47
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
48 Histone Deacetylase Inhibitors Phase 1
49
Lapatinib Approved, Investigational 231277-92-2, 388082-78-8 208908 9941095
50
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast Unknown status NCT00402519 Phase 3
2 A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
3 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
4 A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
5 Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk and Estrogen Receptor-Positive Ductal Carcinoma in Situ of Breast: an International Open-label Randomized Non-inferiority Trial Recruiting NCT04046159 Phase 3 Low-dose tamoxifen
6 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
7 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy Active, not recruiting NCT00769379 Phase 3
8 A Randomised Phase III Study of Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
9 A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
10 Randomised Trial Testing Observation (No Radiotherapy) Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ (DCIS) Of The Breast On Adjuvant Endocrine Therapy Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
11 A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial Completed NCT01194440 Phase 2 letrozole;zoledronic acid
12 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast. Completed NCT03002766 Phase 2
13 Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
14 Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS) Completed NCT01439711 Phase 2 letrozole
15 Primary Hormonal Therapy for Ductal Carcinoma in Situ: Exploration of a Novel Approach to the Clinical Management of Noninvasive Breast Cancer Completed NCT00290745 Phase 1, Phase 2 letrozole;tamoxifen citrate
16 MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS) Completed NCT00586326 Phase 2
17 Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS) Completed NCT00843167 Phase 2
18 Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
19 TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions Recruiting NCT02928978 Phase 2 Ruxolitinib;Placebo (for Ruxolitinib)
20 A Large-scale Multicenter Phase II Study Evaluating the Protective Effect of a Tissue Selective Estrogen Complex (TSEC) in Women With Newly Diagnosed Ductal Carcinoma in Situ Recruiting NCT02694809 Phase 2 Conjugated Estrogens/Bazedoxifene
21 Wide Excision Alone for DCIS-Grades 1 and 2 Active, not recruiting NCT00165256 Phase 2
22 VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast Active, not recruiting NCT02636582 Phase 2 Nelipepimut-S Plus GM-CSF Vaccine
23 Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer Active, not recruiting NCT01266642 Phase 2
24 Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ Not yet recruiting NCT04666961 Phase 2 Tamoxifen 20 mg;Anastrozole 1Mg Tab
25 Identifying the miR Fingerprint in NAF, Serum, and Tissue in Patients With Ductal Carcinoma in Situ (DCIS) or Invasive Breast Cancer Suspended NCT02127073 Phase 2 Intranasal Oxytocin
26 A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ (DCIS) Terminated NCT01060345 Phase 2 Polyphenon E
27 Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor Terminated NCT01372618 Phase 1, Phase 2 SOM 230 / Pasireotide
28 EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast Terminated NCT00082667 Phase 2 gefitinib
29 A Pilot Study of Stereotactic Accelerated Partial Breast Irradiation (SAPBI) for Post-Menopausal Women (>50 y/o) With Ductal Carcinoma in Situ (DCIS) or Early Stage Breast Cancer Terminated NCT02365714 Phase 1, Phase 2
30 Twin Cities Brachytherapy Study for Ductal Carcinoma in Situ A Phase II Trial Terminated NCT00290654 Phase 2 Tamoxifen
31 A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) Terminated NCT00183963 Phase 2 Tamoxifen;Fulvestrant;Fulvestrant
32 A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery Completed NCT02391194 Phase 1 AVB-620
33 A Window Trial of Vorinostat in Patients With Ductal Carcinoma in Situ (DCIS) of the Breast Completed NCT00788112 Phase 1 vorinostat
34 Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery Active, not recruiting NCT03317405 Phase 1 Endoxifen Hydrochloride
35 Relevance of Mammary MRI in the Preoperative Assessment of Ductal Carcinoma in Situ (DCIS) Unknown status NCT03543397
36 Phase II Study of Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery Unknown status NCT02617082
37 Impact of Radiation Therapy on Breast Conservation in DCIS Completed NCT02248662
38 Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast Completed NCT00496808 Herceptin (Trastuzumab)
39 A Comparison of the Diagnostic Accuracy of Adjunctive Digital Breast Tomosynthesis Versus Adjunctive Contrast Enhanced Breast Magnetic Resonance Imaging in the Preoperative Assessment of Breast Cancer Completed NCT01060085
40 A Multicentre Randomized Controlled Clinical Trial for the Reduction of Acute Skin Reaction in Adjuvant Breast Radiation in Large Breasted Women Using a Prone Technique - The Prone Breast Trial Completed NCT01815476
41 A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ Completed NCT01628536
42 Exploring Effects of Weight Loss on Ductal Carcinoma In Situ Completed NCT02224807
43 Comparative Effectiveness of Sentinel Lymph Node Biopsy (SLNB) for Ductal Carcinoma In Situ (DCIS) Completed NCT02908178
44 A Prospective Randomized Trial to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction Completed NCT01969448 Indocyanine Green
45 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Radiation Therapy Delivery System as the Sole Method of Radiation Therapy or as a Boost for Early Stage Breast Cancer and Ductal Carcinoma In Situ of the Breast Completed NCT01448447
46 Longitudinal Observational Study About the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer Completed NCT03669952
47 An RCT to Determine if APBI, Utilizing 3D CRT, is as Effective as Whole Breast Irradiation Following Breast Conserving Surgery in Women With Ductal Carcinoma in Situ or Invasive Breast Cancer With Negative Axillary Lymph Nodes Completed NCT00282035
48 A Pilot Study of Intraoperative Margin Assessment Comparing Optical Spectroscopy and Frozen Section Analysis for Ductal Carcinoma In Situ of the Breast Completed NCT00214292
49 Management of Ductal Carcinoma in Situ (DCIS) or Pure Micro-invasive (DCIS-MI) Extended Breast, Axillary Node Sentinel Site (GAS) When the Diagnosis is Made by Biopsy and Treatment by Mastectomy Immediately. Descriptive Study Completed NCT01841749
50 Evaluation of the Ductal Carcinoma In Situ Score for Decisions on Radiotherapy in Patients With Low/Intermediate Risk DCIS Completed NCT02766881

Search NIH Clinical Center for Ductal Carcinoma in Situ

Sources

Genetic Tests for Ductal Carcinoma in Situ

About this section

Genetic tests related to Ductal Carcinoma in Situ:

# Genetic test Affiliating Genes
1 Ductal Carcinoma in Situ 29
Sources

Anatomical Context for Ductal Carcinoma in Situ

About this section

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

40
Breast, Lymph Node, Skin, Endothelial, Salivary Gland, Smooth Muscle, Prostate
Sources

Publications for Ductal Carcinoma in Situ

About this section

Articles related to Ductal Carcinoma in Situ:

(show top 50) (show all 6971)
# Title Authors PMID Year
1
Symptomatic ductal carcinoma in situ (DCIS): Upstaging risk and predictors. 61
33360004 2021
2
Adolescent use of hair dyes, straighteners and perms in relation to breast cancer risk. 61
33252833 2021
3
Deep learning-based grading of ductal carcinoma in situ in breast histopathology images. 61
33608619 2021
4
Impact of Cavity Shave Margins on Margin Status in Patients with Pure Ductal Carcinoma In Situ. 61
33346081 2021
5
Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes. 61
33180236 2021
6
Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy. 61
33675490 2021
7
Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence. 61
33140128 2021
8
Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast. 61
33795819 2021
9
The Role of Imaging in Health Screening: Overview, Rationale of Screening, and Screening Economics. 61
32409140 2021
10
The Myoepithelial Cells of Salivary Intercalated Duct-type Intraductal Carcinoma Are Neoplastic: A Study Using Combined Whole-slide Imaging, Immunofluorescence, and RET Fluorescence In Situ Hybridization. 61
33086236 2021
11
The utility of intraoperative retroareolar margin frozen section assessment and the management of atypical epithelial proliferative lesions at the retroareolar margin in nipple-sparing mastectomies. 61
33444902 2021
12
Mixed-Methods Study to Predict Upstaging of DCIS to Invasive Disease on Mammography. 61
32783550 2021
13
Digital Mammography Has Persistently Increased High-Grade and Overall DCIS Detection Without Altering Upgrade Rate. 61
33594910 2021
14
Once Daily Versus Twice Daily External Beam Accelerated Partial Breast Irradiation: A Randomized Prospective Study. 61
33714527 2021
15
Male Breast Cancer in Australia. 61
31957255 2021
16
Postneoadjuvant Pure and Predominantly Pure Intralymphatic Breast Carcinoma: Case Series and Literature Review. 61
33105157 2021
17
Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. 61
33113154 2021
18
Upgrade rate of intraductal papilloma diagnosed on core needle biopsy in a single institution. 61
33159966 2021
19
Cribriform colon cancer: a morphological growth pattern associated with extramural venous invasion, nodal metastases and microsatellite stability. 61
33782192 2021
20
Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation. 61
33654083 2021
21
Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis. 61
33752671 2021
22
Predictors of Reexcision following Breast-Conserving Surgery for Ductal Carcinoma In Situ. 61
32914389 2021
23
The usefulness of ultrafast MRI evaluation for predicting histologic upgrade of ductal carcinoma in situ. 61
33429208 2021
24
Low-grade ductal carcinoma in situ (DCIS) arising in a fibroadenoma of the breast during 5 years follow-up: A case report. 61
33725814 2021
25
National Variations in the Work-Up, Investigation, and Surgical Management of Ductal Carcinoma In Situ of the Breast across Canadian Surgeons. 61
33805352 2021
26
Unmasking the immune microecology of ductal carcinoma in situ with deep learning. 61
33649333 2021
27
Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. 61
33199800 2021
28
Significance of Removing Comedonecrosis as an Exclusion Criterion in Mammary Low-Risk Ductal Carcinoma In Situ Managed in an Active Surveillance Clinical Trial. 61
33769445 2021
29
Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast. 61
33414541 2021
30
Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ. 61
33796401 2021
31
Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement study. 61
33420502 2021
32
Noncalcified Ductal Carcinoma In Situ (DCIS): Rate and Predictors of Upgrade to Invasive Carcinoma. 61
32222328 2021
33
Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in Situ: Results from the UK/ANZ DCIS Trial. 61
33727261 2021
34
Turbo Spin-echo Diffusion-weighted Imaging Compared with Single-shot Echo-planar Diffusion-weighted Imaging: Image Quality and Diagnostic Performance When Differentiating between Ductal Carcinoma in situ and Invasive Ductal Carcinoma. 61
32147641 2021
35
Correction to: Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent. 61
33722249 2021
36
Measurements using mammography and ultrasonography underestimate the size of high-volume ductal carcinoma in situ. 61
33810833 2021
37
Management of ductal carcinoma in situ with accelerated partial breast irradiation brachytherapy: Implications for guideline expansion. 61
33317964 2021
38
An Organotypic Mammary Duct Model Capturing Matrix Mechanics-Dependent Ductal Carcinoma In Situ Progression. 61
33397202 2021
39
ASO Author Reflections: Re-Excision for Ductal Carcinoma In Situ: Who Is at Risk? 61
32946015 2021
40
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. 61
33739848 2021
41
Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. 61
32861439 2021
42
Intraductal Carcinomas of the Salivary Gland. 61
33526215 2021
43
Salivary Intraductal Carcinoma Arising within Intraparotid Lymph Node: A Report of 4 Cases with Identification of a Novel STRN-ALK Fusion. 61
32661669 2021
44
A case of endocrine mucin-producing sweat gland carcinoma with distant metastasis. 61
33660318 2021
45
The nipple-areolar complex: comprehensive imaging review. 61
33077158 2021
46
Predictors of invasive disease in patients preoperatively diagnosed with ductal carcinoma without stromal invasion, with breast magnetic resonance imaging (MRI) and ultrasound (US). 61
33200381 2021
47
Benign Breast Intraductal Papillomas Without Atypia at Core Needle Biopsies: Is Surgical Excision Necessary? 61
32860176 2021
48
Radial Scars and Complex Sclerosing Lesions of the Breast: Prevalence of Malignancy and Natural History Under Active Surveillance. 61
33666811 2021
49
Unusual Radiological Features of a Breast Cancer Patient Presenting with Nipple Discharge in Hong Kong. 61
33532016 2021
50
Breast MRI: False-Negative Results and Missed Opportunities. 61
33739893 2021
Sources

Variations for Ductal Carcinoma in Situ

About this section

Cosmic variations for Ductal Carcinoma in Situ:

9 (show top 50) (show all 369)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149317650 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2403A>T p.K801N 16:72957743-72957743 6
2 COSM87291166 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2403A>T p.K801N 16:72957743-72957743 6
3 COSM102041732 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.-23-6778A>T p.? 16:72957743-72957743 6
4 COSM143944147 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.265C>T p.R89W 17:7674221-7674221 6
5 COSM112254852 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 6
6 COSM122733862 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.422G>A p.R141H 17:7673802-7673802 6
7 COSM144092525 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.110G>C p.R37P 17:7674944-7674944 6
8 COSM112253807 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 6
9 COSM143157019 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.265C>T p.R89W 17:7674221-7674221 6
10 COSM111766786 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 17:7674944-7674944 6
11 COSM144652630 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.467T>C p.I156T 17:7674947-7674947 6
12 COSM144650760 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.701G>A p.R234H 17:7673802-7673802 6
13 COSM121875541 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.422G>A p.R141H 17:7673802-7673802 6
14 COSM144092363 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.359G>A p.G120E 17:7673784-7673784 6
15 COSM142837551 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 6
16 COSM122734399 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.346C>T p.R116W 17:7674221-7674221 6
17 COSM87900157 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 17:7673802-7673802 6
18 COSM105621872 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 6
19 COSM106053434 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 6
20 COSM144015040 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.785G>T p.R262L 17:7673802-7673802 6
21 COSM93185256 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 17:7673802-7673802 6
22 COSM93190437 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.517G>T p.V173L 17:7675095-7675095 6
23 COSM145017944 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.625C>T p.R209W 17:7674221-7674221 6
24 COSM111758868 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 6
25 COSM142837352 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 17:7674220-7674220 6
26 COSM144087106 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.266G>A p.R89Q 17:7674220-7674220 6
27 COSM145018679 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.707G>T p.C236F 17:7673796-7673796 6
28 COSM121876459 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.346C>T p.R116W 17:7674221-7674221 6
29 COSM93191567 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 17:7674944-7674944 6
30 COSM144048390 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.678G>C p.M226I 17:7674252-7674252 6
31 COSM142837497 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 6
32 COSM144651436 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.625C>T p.R209W 17:7674221-7674221 6
33 COSM105667399 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 6
34 COSM144013367 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.710G>A p.R237Q 17:7674220-7674220 6
35 COSM144026584 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.499C>G p.H167D 17:7675080-7675080 6
36 COSM112253879 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 6
37 COSM143378524 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.719G>A p.G240E 17:7673784-7673784 6
38 COSM111759630 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.797G>A p.G266E 17:7673823-7673823 6
39 COSM142560553 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.625C>T p.R209W 17:7674221-7674221 6
40 COSM143945376 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.341G>T p.R114L 17:7673802-7673802 6
41 COSM142866376 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 6
42 COSM93183281 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>A p.R273H 17:7673802-7673802 6
43 COSM143156843 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.266G>A p.R89Q 17:7674220-7674220 6
44 COSM111797204 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 6
45 COSM87898709 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 6
46 COSM105620276 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 17:7674220-7674220 6
47 COSM122748281 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.136C>G p.H46D 17:7675080-7675080 6
48 COSM106067001 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.532C>G p.H178D 17:7675080-7675080 6
49 COSM145024750 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.400G>T p.V134L 17:7675095-7675095 6
50 COSM144014340 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.791G>T p.C264F 17:7673796-7673796 6
Sources

Expression for Ductal Carcinoma in Situ

About this section
Search GEO for disease gene expression data for Ductal Carcinoma in Situ.
Sources

Pathways for Ductal Carcinoma in Situ

About this section

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.09 TP53 S100A7 PTGS2 MUC1 ERBB2 EGFR
2
ERK Signaling 63
Show member pathways
 13.84 TP53 PTGS2 MUC1 ESR1 ERBB2 EGFR
3
GPCR Pathway 63
Show member pathways
 13.73 TP53 PTGS2 ESR1 ERBB2 EGFR EGF
4
Cytokine Signaling in Immune system 65
Show member pathways
 13.41 TP53 PTGS2 MUC1 ERBB2 EGFR EGF
5
PI3K-Akt signaling pathway 36
Show member pathways
 13.02 TP53 PTGS2 ERBB2 EGFR EGF CCND1
6
Human cytomegalovirus infection 36
Show member pathways
 13.01 TP53 PTGS2 EGFR CDKN2A CCND1 AKT1
7
Focal Adhesion 36 1
Show member pathways
 12.96 PTGS2 ERBB2 EGFR EGF CCND1 AKT1
8
Endometrial cancer 36
Show member pathways
 12.88 TP53 ERBB2 EGFR EGF CDKN2A CDH1
9
MAPK signaling pathway 36 1
12.82 TP53 ERBB2 EGFR EGF AKT1
10
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.78 TP53 ERBB2 EGFR EGF AKT1
11
Development HGF signaling pathway 23
Show member pathways
 12.78 TP53 PTGS2 ESR1 ERBB2 CDH1 AKT1
12
Chks in Checkpoint Regulation 63
Show member pathways
 12.75 TP53 ESR1 CCND1 BRCA2 BRCA1
13
Relaxin signaling pathway 36
Show member pathways
 12.73 PGR KRT14 ESR1 EGFR AKT1
14
Pathways in cancer 36
12.72 TP53 PTGS2 ESR1 ERBB2 EGFR EGF
15
ErbB signaling pathway 36 1
Show member pathways
 12.69 TP53 ERBB2 EGFR EGF CCND1 AKT1
16
DNA Damage 4
12.57 TP53 CDKN2A CCND1 BRCA2 BRCA1
17
VEGF Signaling 66
Show member pathways
 12.57 TP53 MUC1 EGFR EGF CDH1 AKT1
18
MicroRNAs in cancer 36
12.55 TP53 PTGS2 ERBB2 EGFR CDKN2A CD44
19
Glioma 36
Show member pathways
 12.5 TP53 ESR1 ERBB2 EGFR EGF CDKN2A
20
WNT Signaling 63
12.48 TP53 PTGS2 CDH1 CCND1 AKT1
21
JAK-STAT signaling pathway 36
Show member pathways
 12.46 EGFR EGF CCND1 AKT1
22
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.46 PTGS2 ESR1 CD44 BRCA1 AKT1
23
Shigellosis 36
12.45 TP53 EGFR CD44 AKT1
24
DNA Damage Response 1
Show member pathways
 12.43 TP53 CDKN2A CCND1 BRCA1
25
Cell cycle 36 1
12.42 TP53 CDKN2A CDH1 CCND1
26
Human T-cell leukemia virus 1 infection 36
12.39 TP53 CDKN2A CCND1 AKT1
27
Development ERBB-family signaling 23
Show member pathways
 12.39 MUC1 ERBB2 EGFR EGF CDH1 AKT1
28
Development Ligand-independent activation of ESR1 and ESR2 23
Show member pathways
 12.38 PTGS2 ESR1 ERBB2 EGFR EGF CCND1
29
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 12.36 TP53 ERBB2 EGFR EGF CCND1 AKT1
30
Signaling by ERBB2 65
Show member pathways
 12.35 ERBB2 EGFR EGF AKT1
31
Proteoglycans in cancer 36
12.35 TP53 ESR1 ERBB2 EGFR CD44 CCND1
32
p53 Signaling 63
Show member pathways
 12.31 TP53 CCND1 BRCA1 AKT1
33
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.3 TP53 ERBB2 EGFR CCND1 AKT1
34
Cell cycle Role of SCF complex in cell cycle regulation 23
Show member pathways
 12.29 PGR ESR1 CDKN2A CCND1 BRCA1
35
EGF/EGFR Signaling Pathway 1
12.25 ERBB2 EGFR EGF AKT1
36
Cellular senescence (KEGG) 36
12.22 TP53 CDKN2A CCND1 AKT1
37
Development EGFR signaling via small GTPases 23
Show member pathways
 12.2 ERBB2 EGFR EGF AKT1
38
Colorectal Cancer Metastasis 63
12.17 TP53 PTGS2 EGFR EGF CDH1 CCND1
39
FoxO signaling pathway 36
Show member pathways
 12.15 EGFR EGF CCND1 AKT1
40
Signaling by PTK6 65
Show member pathways
 12.13 ERBB2 EGFR EGF CCND1 AKT1
41
MAPK Pathway 69
Show member pathways
 12.1 TP53 ERBB2 EGFR AKT1
42
Thyroid hormone signaling pathway 36
12.08 TP53 ESR1 CCND1 AKT1
43
Spinal Cord Injury 1
12.07 TP53 PTGS2 EGFR CCND1
44
Gastric cancer 36
Show member pathways
 12.07 TP53 PGR ESR1 ERBB2 EGFR EGF
45
DNA Damage Response (only ATM dependent) 1
12.06 TP53 ERBB2 CDKN2A CCND1 AKT1
46
Interleukin-4 and 13 signaling 65
12.05 TP53 PTGS2 MUC1 CCND1 AKT1
47
Glioblastoma Multiforme 63
12.05 TP53 EGFR EGF CDKN2A CCND1 AKT1
48
HIF-1 signaling pathway 36
12.02 ERBB2 EGFR EGF AKT1
49
S-1P Stimulated Signaling 63
12.01 EGFR EGF CDH1 AKT1
50
Signaling by ERBB4 65
Show member pathways
 12.01 PGR ESR1 ERBB2 EGFR EGF
Sources

GO Terms for Ductal Carcinoma in Situ

About this section

Cellular components related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.16 TP53 PTGS2 PGR MUC1 KRT5 ESR1
2 nucleus GO:0005634 10.03 TP53 S100A7 PTGS2 PGR MUC1 KRT5
3 cytoplasm GO:0005737 9.86 TP53 S100A7 PTGS2 PGR MUC1 KRT5
4 basolateral plasma membrane GO:0016323 9.62 ERBB2 EGFR CLDN7 CD44
5 protein-containing complex GO:0032991 9.23 TP53 PTGS2 ESR1 EGFR CDKN2A BRCA2

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 TP53 PGR ESR1 EGFR CDKN2A BRCA1
2 cellular response to DNA damage stimulus GO:0006974 10.09 TP53 CCND1 BRCA2 BRCA1 AKT1
3 negative regulation of apoptotic process GO:0043066 10.04 TP53 PTGS2 EGFR CLDN7 CD44 AKT1
4 cytokine-mediated signaling pathway GO:0019221 9.97 TP53 PTGS2 MUC1 CCND1 AKT1
5 positive regulation of gene expression GO:0010628 9.97 TP53 ERBB2 EGF CDKN2A BRCA1 AKT1
6 positive regulation of protein phosphorylation GO:0001934 9.96 ERBB2 EGFR CCND1 AKT1
7 positive regulation of protein kinase B signaling GO:0051897 9.93 ESR1 ERBB2 EGFR EGF
8 positive regulation of cell proliferation GO:0008284 9.91 PTGS2 ERBB2 EGFR EGF CLDN7 CCND1
9 response to oxidative stress GO:0006979 9.88 TP53 PTGS2 EGFR AKT1
10 cellular response to mechanical stimulus GO:0071260 9.85 PTGS2 EGFR AKT1
11 positive regulation of kinase activity GO:0033674 9.85 ERBB2 EGFR CD44
12 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.85 PTGS2 CD44 AKT1
13 cellular response to growth factor stimulus GO:0071363 9.84 ERBB2 EGFR AKT1
14 double-strand break repair GO:0006302 9.84 TP53 BRCA2 BRCA1
15 response to estrogen GO:0043627 9.83 ESR1 CCND1 BRCA1
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.82 PTGS2 EGFR AKT1
17 positive regulation of MAP kinase activity GO:0043406 9.81 ERBB2 EGFR EGF
18 epidermal growth factor receptor signaling pathway GO:0007173 9.8 EGFR EGF AKT1
19 cellular response to epidermal growth factor stimulus GO:0071364 9.78 ERBB2 EGFR AKT1
20 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 PTGS2 EGFR CD44 AKT1
21 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.77 EGFR CCND1 AKT1
22 negative regulation of Notch signaling pathway GO:0045746 9.77 EGFR EGF AKT1
23 response to organic substance GO:0010033 9.76 PTGS2 CDH1 CCND1 AKT1
24 positive regulation of vasoconstriction GO:0045907 9.73 PTGS2 EGFR AKT1
25 positive regulation of cell cycle arrest GO:0071158 9.72 TP53 CDKN2A BRCA1
26 response to estradiol GO:0032355 9.72 PTGS2 ESR1 EGFR CYP19A1 CCND1
27 regulation of cell motility GO:2000145 9.71 ERBB2 EGFR EGF
28 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.7 EGFR CCND1 AKT1
29 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.69 TP53 ESR1
30 ERBB2 signaling pathway GO:0038128 9.69 ERBB2 EGFR EGF
31 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.68 TP53 ESR1
32 intracellular steroid hormone receptor signaling pathway GO:0030518 9.68 PGR ESR1
33 mitotic G1 DNA damage checkpoint GO:0031571 9.67 TP53 CCND1
34 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.64 TP53 MUC1
35 cellular response to indole-3-methanol GO:0071681 9.62 CDH1 BRCA1
36 chordate embryonic development GO:0043009 9.62 BRCA2 BRCA1
37 negative regulation of immature T cell proliferation in thymus GO:0033088 9.61 ERBB2 CDKN2A
38 response to X-ray GO:0010165 9.61 TP53 CCND1 BRCA2
39 positive regulation of transcription, DNA-templated GO:0045893 9.61 TP53 ESR1 EGFR EGF CDKN2A CDH1
40 mammary gland alveolus development GO:0060749 9.58 ESR1 EGF CCND1
41 negative regulation of ERBB signaling pathway GO:1901185 9.43 ERBB2 EGFR EGF
42 response to UV-A GO:0070141 9.33 EGFR CCND1 AKT1
43 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.92 TP53 MUC1 BRCA2 BRCA1

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.85 TP53 PGR ESR1 ERBB2 EGFR CLDN7
2 protein kinase binding GO:0019901 9.73 TP53 ESR1 EGFR CDKN2A CCND1 AKT1
3 p53 binding GO:0002039 9.5 TP53 MUC1 CDKN2A
4 MDM2/MDM4 family protein binding GO:0097371 9.37 TP53 CDKN2A
5 enzyme binding GO:0019899 9.23 TP53 PTGS2 PGR ESR1 EGFR CCND1
6 nitric-oxide synthase regulator activity GO:0030235 9.13 ESR1 EGFR AKT1
Sources

Sources for Ductal Carcinoma in Situ

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....